0001209191-19-050729.txt : 20190925 0001209191-19-050729.hdr.sgml : 20190925 20190925181141 ACCESSION NUMBER: 0001209191-19-050729 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190923 FILED AS OF DATE: 20190925 DATE AS OF CHANGE: 20190925 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LANGE LOUIS G CENTRAL INDEX KEY: 0001238401 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 191115145 MAIL ADDRESS: STREET 1: 3172 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94034 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-23 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001238401 LANGE LOUIS G C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 1 0 0 0 Common Stock 2019-09-23 4 S 0 9755 32.149 D 276044 D Common Stock 2019-09-23 4 S 0 245 32.6628 D 275799 D Common Stock 2019-09-23 4 S 0 1000 32.182 D 14678 I By Amygdala Lange Trust Common Stock 32343 I By Asset Management Ventures Fund, L.P. Common Stock 3555 I By Adrienne M. MacMillan Revocable Trust This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. The lowest price at which shares were sold was $31.61 and the highest price at which shares were sold was $32.59. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Represents the weighted average sale price. The lowest price at which shares were sold was $32.615 and the highest price at which shares were sold was $32.705. Represents the weighted average sale price. The lowest price at which shares were sold was $31.68 and the highest price at which shares were sold was $32.60. The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. /s/ Mark Meltz as attorney-in-fact for Louis Lange, M.D., Ph.D. 2019-09-25